司美格鲁肽渐进滴定可提高治疗依从性并减少不良事件:一项比较16周灵活滴定方案与标签推荐8周滴定方案的随机对照开放标签先导研究
该随机对照开放标签先导研究纳入104例2型糖尿病患者,比较标签推荐滴定方案(0.25 mg、0.5 mg、1 mg,每4周递增)与灵活滴定方案(起始0.0675 mg,每周递增0.0675 mg,出现胃肠道不良事件时延迟递增)共26周。结果显示灵活滴定组因胃肠道不良事件退出者仅2%,标签组为19%(P=0.005);灵活组恶心报告率45.1%对64.2%(P=0.051),乏力9.8%对24.5%(P=0.047),恶心天数2.88天对6.3天(P=0.017);两组最终剂量、HbA1c和BMI变化相似。
要点
- 灵活滴定组因胃肠道不良事件退出2%,标签组19%(P=0.005)。
- 灵活滴定组恶心报告率45.1%对64.2%(P=0.051),乏力9.8%对24.5%(P=0.047)。
- 两组最终剂量、HbA1c和BMI变化相似。
核心结论
- 较慢的灵活滴定方案提高了治疗依从性并减少了不良事件,且未影响疗效。
研究设计与样本
- 随机对照开放标签先导研究,共纳入104例2型糖尿病患者,随机分为标签推荐滴定组或灵活滴定组,干预26周。
主要发现
- 灵活滴定组因胃肠道不良事件退出者2%,标签推荐组为19%(P=0.005)。
- 灵活滴定组恶心报告率45.1%,标签推荐组为64.2%(P=0.051)。
- 灵活滴定组乏力报告率9.8%,标签推荐组为24.5%(P=0.047)。
- 灵活滴定组出现恶心的天数为2.88天,标签推荐组为6.3天(P=0.017)。
- 两组最终剂量、HbA1c和BMI变化相似。
关键数值与推荐
- 标签推荐滴定方案:0.25 mg、0.5 mg、1 mg,每4周递增一次。
- 灵活滴定方案:起始0.0675 mg(以剂量选择旋钮的五格为准),每周递增0.0675 mg,出现胃肠道不良事件时延迟递增。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether a slower, flexible titration regimen of semaglutide would improve adherence and reduce gastrointestinal adverse events (GI-AEs) compared with the label-recommended regimen in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: A total of 104 patients with T2D were randomized to label-recommended titration (0.25 mg, 0.5 mg, 1 mg at 4-week intervals) or flexible titration (starting at 0.0675 mg [measured as five clicks made by the dose selector dial], with gradual increases by 0.0675 mg/week and delays for GI-AEs) for 26 weeks. RESULTS: While final doses were similar between groups, only 2% of patients in the flexible arm withdrew due to GI-AEs vs. 19% in the label arm (P = 0.005). The flexible arm reported less nausea (45.1% vs. 64.2%; P = 0.051) and asthenia (9.8% vs. 24.5%; P = 0.047), with fewer days experiencing nausea (2.88 vs. 6.3 days; P = 0.017). HbA1c and BMI changes were similar between groups. CONCLUSIONS: Slower, flexible titration improved adherence and reduced adverse events without compromising efficacy.
引用
- Eldor R, Avraham N, Rosenberg O, et al. Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen. Diabetes Care. 2025. PMID: 40673973. doi:10.2337/dc25-0690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。